| Human Arylamine N-Acetyltransferase Genes: Isolation, Chromosomal Localization, and Functional Expression M Blum, DM Grant, W McBride, M Heim, UA Meyer DNA and cell biology 9 (3), 193-203, 1990 | 544 | 1990 |
| Nomenclature for N-acetyltransferases KP Vatsis, WW Weber, DA Bell, JM Dupret, DAP Evans, DM Grant, ... Pharmacogenetics and Genomics 5 (1), 1-17, 1995 | 471 | 1995 |
| Molecular mechanism of slow acetylation of drugs and carcinogens in humans. M Blum, A Demierre, DM Grant, M Heim, UA Meyer Proceedings of the National Academy of Sciences 88 (12), 5237-5241, 1991 | 456 | 1991 |
| Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity NH SHEAR, SP SPIELBERG, DM GRANT, BK TANG, W KALOW Annals of Internal Medicine 105 (2), 179-184, 1986 | 427 | 1986 |
| Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases DW Hein, MA Doll, TD Rustan, K Gray, Y Feng, RJ Ferguson, DM Grant Carcinogenesis 14 (8), 1633-1638, 1993 | 384 | 1993 |
| Variability in caffeine metabolism DM Grant, BK Tang, W Kalow Clinical Pharmacology & Therapeutics 33 (5), 591-602, 1983 | 338 | 1983 |
| Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. DM Grant, M Blum, M Beer, UA Meyer Molecular pharmacology 39 (2), 184-191, 1991 | 309 | 1991 |
| Human acetyltransferase polymorphisms DM Grant, NC Hughes, SA Janezic, GH Goodfellow, HJ Chen, A Gaedigk, ... Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 376 (1 …, 1997 | 303 | 1997 |
| Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome (s) P-450 in human liver microsomes. ME Campbell, DM Grant, T Inaba, W Kalow Drug Metabolism and Disposition 15 (2), 237-249, 1987 | 260 | 1987 |
| A simple test for acetylator phenotype using caffeine. DM Grant, BK Tang, W Kalow British journal of clinical pharmacology 17 (4), 459-464, 1984 | 235 | 1984 |
| Principles of medical pharmacology AJ Atkinson | 181 | 2006 |
| Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. DM Grant, K Mörike, M Eichelbaum, UA Meyer The Journal of clinical investigation 85 (3), 968-972, 1990 | 161 | 1990 |
| Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. A Gaedigk, SP Spielberg, DM Grant Pharmacogenetics 4 (3), 142-153, 1994 | 157 | 1994 |
| Localization of N-Acetyltransferases NAT1 and NAT2 in Human Tissues KF Windmill, A Gaedigk, P de la M. Hall, H Samaratunga, DM Grant, ... Toxicological Sciences 54 (1), 19-29, 2000 | 156 | 2000 |
| Molecular genetics of the N-acetyltransferases DM Grant Pharmacogenetics and Genomics 3 (1), 45-50, 1993 | 151 | 1993 |
| The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies KF Windmill, RA McKinnon, X Zhu, A Gaedigk, DM Grant, ME McManus Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 376 (1 …, 1997 | 147 | 1997 |
| Genetic polymorphisms of drug metabolism UA Meyer Fundamental & clinical pharmacology 4 (6), 595-615, 1990 | 147 | 1990 |
| Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. NC Hughes, SA Janezic, KL McQueen, MA Jewett, T Castranio, DA Bell, ... Pharmacogenetics 8 (1), 55-66, 1998 | 146 | 1998 |
| Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism … JM Dupret, DM Grant Journal of Biological Chemistry 267 (11), 7381-7385, 1992 | 143 | 1992 |
| Update on consensus arylamine N-acetyltransferase gene nomenclature DW Hein, DM Grant, E Sim Pharmacogenetics and Genomics 10 (4), 291-292, 2000 | 136 | 2000 |
